AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant medication
Description: Record of concomitant medications used.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concomitant medication
Description: Record of concomitant medications used.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adverse events
Description: Collection and recording of adverse events.
Study NCT06676410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse events
Description: Collection and recording of adverse events.
Study NCT06676410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretrovirals
Description: Tenofovir - inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate, deoxyadenosine 5'-triphosphate and, upon incorporation into DNA, causes DNA chain termination.~* Lamivudine - potent selective inhibitor of HIV-1 and HIV-2 replication in vitro.~* Darunavir - prevents the formation of mature infective viral particles, indicated for the treatment of the human immunodeficiency virus (HIV), which causes AIDS.~* Ritonavir: antiretroviral protease inhibitor, widely used in combination with other protease inhibitors in the therapy and prevention of HIV infection, which causes the syndrome acquired immunodeficiency (AIDS).~* Single solid formulation (in 1 tablet) 1x/day with:~* Tenofovir (TDF) 300 mg~* Lamivudine (3TC) 300 mg~* Darunavir (DRV) 800 mg, 1x/day~* Ritonavir (RTV) 100 mg, 1x/day
Study NCT06676423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzumestrocel
Description: 1.0 ⅹ 10\^6 cells/kg of Neuronata-R mixed with HTS-FRS suspension are administered twice in the cerebrospinal fluid at intervals of 26 days
Study NCT05477953 — intervention group
Intervention type: DRUG
Intervention: Nifurtimox (BAYA2502)
Description: At least 1 dose of nifurtimox
Study NCT05262192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: Nutrition education will be given to the patients in the experimental group.
Study NCT05832216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a monoclonal globulin targeting the CD38 molecule of immune cells, which can eliminate antigen-presenting cells such as dendritic cells and macrophages, and indirectly reduce the production of autoantibodies. In addition, Daratumumab reduces autoantibody levels by targeting plasma cells, B lymphocytes and T lymphocytes.
Study NCT06676423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: In the case of a subject who is not taking Riluzole at the time of screening (visit 1), Riluzole should be taken except when discontinued due to Adverse events. The dose can be changed within the authorization according to the medical expert's judgement
Study NCT05256641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT05297864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: The starting dose will be 300 mg niraparib (or modified according patient weight and platelet count), taken orally once a day for each cycle of 28 days.
Study NCT06629155 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared oculography
Description: Eye movements will be captured through infrared oculography and processed via in-house algorithms.
Study NCT06085755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan will be administered 6.4mg/kg or 5.4mg/kg iv infusion q 3weeks as one cycle.
Study NCT06085755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally 20mg \~40mg once a day or three times a week(Monday, Wednesday, Friday \[MWF\]) or twice weekly (Monday, Thursday \[MT\]) for 3weeks as one cycle.
Study NCT06219369 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group T
Description: SPSIPB Technique:~The SPSIPB block, which follows the guidelines we routinely use, will be performed after the completion of the surgical procedure and before the patient wakes up.~TPVB Technique:~The US probe (11-12 MHz, Vivid Q) will be placed 2-3 cm lateral to the T5 spinous process. After visualizing the transverse process, the paravertebral area, internal intercostal membrane, paravertebral space, and pleura, the needle will be advanced to the paravertebral space using an in-plane technique.
Study NCT06300528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
Study NCT00992238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoxate Hydrochloride Tablets, 100mg
Study NCT00992238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urispas® Tablets, 100mg
Study NCT05572801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMR B: HPV positive ctDNA guided imaging in follow-up
Description: Blood samples in follow-up positive for ctDNA leads to an extra PET-CT scan to detect early treatment failure
Study NCT05022862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
Study NCT05022862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Medication is dispensed to participant at each visit in 30-60 day supplies by Baltimore City Health Department (BCHD) nurses. For study participants, medication dispensation will occur in medication bottles with MEMS Caps, supplied by the study.
Study NCT05022862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Directly Observed Therapy alone
Description: Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
Study NCT05022862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy alone
Description: Usual care plus Video-DOT using the emocha platform, a HIPAA compliant commercial platform for video based DOT. The app allows a secure/encrypted video recording to be taken as the participant ingests the medication. Electronic text reminders will be sent to the participant on the smart phone when it is time to take the medication. The participant will record a video of the pill ingestion process. Study staff will verify each video to confirm the video shows the correct person and that the pill was ingested appropriately (according to standardized approach involving visualization of the pills, ingestion and observation of an empty mouth after ingestion).
Study NCT05022862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy plus Financial Incentives
Description: Usual care plus video-DOT and financial incentives contingent on adherence verified by video DOT. The amount of the financial incentive that can be earned for future verified doses decreases after a missed dose (video). The amount of the financial incentives increases incrementally back to baseline amount after verification of medication ingestion according to the prescribed schedule for several consecutive doses.
Study NCT05612048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: This is a 15-item questionnaire. The questionnaire asks subjects to quantify, during a specified duration of time, the number of times they have consumed or completed a task (ex. alcohol intake, cigarette use, and teeth brushing frequency). Additionally, the questionnaire further asks subjects to quantify their GERD symptoms and risk factors prior to diagnosis. All study procedures will be completed in one visit as part of a standard-of-care clinic visit.
Study NCT05612048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-oral camera
Description: Intraoral pictures of molars and incisors in 13 key regions
Study NCT05612048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optional Salvia sample
Description: Cohort 1 only. Participant is responsible for collecting and bringing the salvia sample to clinic.
Study NCT06241989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education supported by motivational interviewing
Description: The intervention group will receive health education supported by motivational interviewing consisting of 6 sessions. Within the scope of the intervention, the first two sessions will be health education and the last four sessions will be motivational interviewing.
Study NCT05185830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive robots
Description: Children will mobilize with the interactive robot when control group will mobilize with nurse.
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 12 μg
Description: CVGBM will be administered as an IM injection.
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 25 μg
Description: CVGBM will be administered as an IM injection.
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 50 μg
Description: CVGBM will be administered as an IM injection.
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 100 μg
Description: CVGBM will be administered as an IM injection.
Study NCT06084169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra Ocular Lens (IOL) Implant
Description: Implantable intra ocular lens instead of the cataractous lens has been removed from the patient's eye
Study NCT06027567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous once-weekly injections of Semaglutide uptitrating to a maximum of 2.4 mg
Study NCT06027567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: Very Low Calorie Diet (max 800 kcal/day) using Nupo Diet meal replacement products
Study NCT06027567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietician counselling
Description: Counselling by a dietician on weight loss through behavioural changes and life style intervention
Study NCT06027567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietician counselling
Description: Counselling by a dietician on weight loss through behavioural changes and life style intervention
Study NCT04600713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT-X and IMT
Description: The intervention consists of PT-X, including central circulatory exercise and muscle exercises, 2 times/week, 60 min/session for 12 weeks, and homebased exercises 2 times/week logged in an exercise diary. For IMT the Threshold Inspiratory Muscle Trainer (Threshold IMT) (Respironics Inc., Murrysville, PA, USA) will be used at 30 % of maximal expiratory pressure in 15 minutes 2 times a day during 12 weeks.
Study NCT05699226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical Incorporated 4x1 adapter
Description: Device permits individualized amplitudes
Study NCT05699226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ECT device
Description: FDA approved ECT device with fixed amplitude.
Study NCT06555393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg White Powder
Description: Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption.
Study NCT06555393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Egg White Powder
Description: Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption.
Study NCT06555393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg White Powder
Description: Participants will consume a standardized breakfast (2 slices of 70 g whole wheat bread, 10 g of butter and 30 g of strawberry jam) followed by a smoothie containing the powder. The Egg White Powder will be incorporated in the standardized smoothie containing water, fruits and chocolate/strawberry syrup totaling 250 Kcal. The total calories of the breakfast will be adapted to the calorie needs of each participant to account for 20-25% of their daily calorie intake.~After a 9 h fast, blood will be taken before consumption of the standardized breakfast and smoothie (T= 0) and at 5, 10, 20, 30, 60, 90, 120, and 180 min after consumption of the smoothie. Participants will be given 15-25 minutes to eat their breakfast. Urine samples will be collected from participants before the smoothie consumption (0 h) and at 30 min, 90 min, 150 min, 6 hours, 12 hours, and 24 hours following consumption.
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine RDE 100 μg
Description: CVGBM will be administered as an IM injection.
Study NCT05892341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AQUACEL® Ag+ Extra™
Description: Wound treatment with AQUACEL® Ag+ Extra™ dressing
Study NCT05938387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV09050101 mRNA vaccine (CVGBM) 6 μg
Description: CVGBM will be administered as an IM injection.
Study NCT05892341 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutimed® Sorbact®
Description: Wound treatment with Cutimed® Sorbact® dressing
Study NCT05176509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be administered intravenously over 60 minutes every 21-day cycle.
Study NCT05176509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH001
Description: YH001 will be administered intravenously over 60 minutes every 21-day cycle.
Study NCT05176509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.
Study NCT05703230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured preoperative multidisciplinary team meeting
Description: The intervention to be investigated is the introduction of a preoperative structured multidisciplinary team (sMDT) meeting for high risk noncardiac surgical patients, which is attended by at least the treating surgical specialist, an anesthesiologist and another medical consultant with expertise relevant for the patients comorbidities and preferences. In the preoperative sMDT meeting, at least the following questions will be discussed as recommended by the Dutch Perioperative Guideline:~* Is the proposed surgical intervention appropriate care for the patient?~* Is the risk/benefit ratio of the proposed surgical intervention acceptable for the patient?~* Should the patient's condition be optimized before undergoing the proposed surgical intervention?
Study NCT05054673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: universal adhesive
Description: PALFIQUE universal adhesive
Study NCT05054673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: universal adhesive
Description: 3M™ ESPE™ single bond Universal Adhesive
Study NCT05685641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histoplasma Urine Antigen Lateral Flow Antigen test
Description: Lateral Flow Antigen test for urine samples to detect Histoplasma capsulatum disseminated disease
Study NCT05685641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cryptococcal Lateral Flow Antigen test
Description: Lateral Flow Antigen test for serum or cerebrospinal fluid samples to detect Cryptococcus sp meningitis or disseminated disease
Study NCT05685641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tuberculosis-lipoarabinomannan Lateral Flow Antigen test
Description: Lateral Flow Antigen test for serum samples to detect Mycobacterium tuberculosus disease
Study NCT06281782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical retinoids and platalet rich plasma
Description: We will analyse both monotherapy with a topical retinoid alone and combination therapy with a topical retinoid and platelet-rich plasma (PRP) to elucidate their role in acne treatment and provide possible recommendations for their use.
Study NCT05214898 — intervention group
Intervention type: BEHAVIORAL
Intervention: 24/7 Dad
Description: The 24/7 Dad curriculum is an evidence-based, skills driven curriculum (12 group sessions). The following topics are included: Family History, What it Means to Be a Man, Showing and Handling Feelings, Men's Health, Communication, The Father's Role, Discipline, Children's Growth, Getting Involved, Working with \& Co-Parenting, Dads and Work, and the My 24/7Dad Checklist. Healthy Relationship topics include: Communication Skills, including expression, discussion, and negotiation skills; Conflict Resolution and Anger Management; Problem-Solving; and Knowledge of the Benefits of Marriage. Responsible Parenting areas of focus include: children's growth/development; non-violent discipline; co-parenting; building conflict resolutions skills (for the child and the family); and, enhancing family relationships.
Study NCT05477420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants in the experimental group would be asked to use the decision aid developed by the study. The decision aid tool will ask participants their preferences on traditional face-to-face and online psychotherapies and how they rank different treatment attributes.
Study NCT05093608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor Pill
Description: Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
Study NCT05093608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
Study NCT05093608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
Study NCT04866303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home-based SARS-CoV-2 test kit
Description: A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.
Study NCT06385886 — intervention group
Intervention type: BEHAVIORAL
Intervention: Linkage Coordinator
Description: The Linkage Coordinator (LC) will be the initial contact with unaffiliated SCD patients to establish a relationship, champion preventative services, and support them in engaging with an SCD specialist by helping patients address barriers to care. Study staff will provide initial and ongoing training to the LC to ensure they have adequate support to effectively engage with patients.
Study NCT06561139 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Weekly group sessions of mindfulness, for eight weeks
Study NCT06561139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Weekly group sessions of mindfulness, for eight weeks
Study NCT06005402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSX-1004
Description: Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs
Study NCT06005402 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline for injection
Study NCT06479356 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relma-cel
Description: Relma-cel will be administered at one dose level:1×10\^8 CAR+T cells